Resultados de investigación

Presentación de la sessión Plenaria 4 a cargo de Carles Llop, Director del Congreso. Moderadores de la sesión: Mosé Ricci (Univesidad de Trento) y Manuel Gausa (Universidad de Génova). SAB) y Miquel Martí: Ponentes: Patrizia Gabellii; Arturo Lanzani; Maria Chiara Tosi. (Ponencias en italiano con traducción subtitulada al castellano), Objectius de Desenvolupament Sostenible::11 - Ciutats i Comunitats Sostenibles

Més informació a: / Más información en: https://segues.upc.edu/es/jornadas-segues/segues20

Més informació a: / Más información en: https://segues.upc.edu/es/jornadas-segues/segues20

El Foment Vilanoví organitza el primer Tribuna en format telemàtic amb la col·laboració de l'EPSEVG amb la Dra. Clara Prats. Clara Prats, llicenciada en Física per la Universitat de Barcelona i doctora en Física Aplicada i Simulació en Ciències per la Universitat Politècnica de Catalunya (UPC). Actualment és professora agregada de la UPC. Investigadora del grup de Biologia Computacional i Sistemes Complexos de la UPC, i responsable de models computacionals al Centre de Medicina Comparativa i Bioimatge de l’Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP). La seva línia de recerca se centra en l’ús de la modelització computacional per a l’estudi de malalties infeccioses, principalment la tuberculosi, però també la malària, la malaltia del Chagas i, els últims mesos, la COVID-19. En col·laboració amb el Diari de Vilanova es va crear Tribuna Vilanova, un espai on dialogar amb persones d’interès rellevant a Vilanova i la Geltrú i Catalunya de diferents àmbits d’activitat: social, jurídic, cívic, artístic, literari, entre d'altres.

Postprint (author's final draft)

Conjunt editat de fragments sonors de 40 gravacions de regal enviades pel sant de Francesc Daumal el dia 2 d'abril de 2020., La simultània embolcallada per a regal és una obra artística basada en 40 paisatges sonors reals provinents de tot el món, que s’han gravat simultàniament a migdia del dia del meu sant, el 2 d’abril del 2020, en plena pandèmia. La gravació final, de 3 minuts d’extensió en total, té 40 talls sonors, de 4,5 segons cadascún, empalmats de forma consecutiva, respectant l’ordre en que es vàren recepcionar les gravacions originals. Els autors han cedit els seus drets per a poder fer aquest compendi, en el que ha participat molt activament el tècnic de so Hèctor Balart Armengol, compatibilitzant els diferents llenguatges de cada deriva sonora, i fent l’elecció aleatòria dels seus valors estètics més representatius. Aquesta obra s’hapresentat com a primicia el 14 d’octubre 2020, a la Biennal del Pensament de l’Ajuntament de Barcelona, per a la taula rodona Sons, Sorolls, Silencis. Cap a una ecología acústica urbana en l’era digital. Participants: Francesc Daumal i Domènech, Fernando Valdés, Rosa María Alsina, Antonio de Clemente, Vicent Matamoros, Laura Puig, Oriol Server Yerga, Carlos Gómez Caballero, Valentin Martín Fanjul, Belen Casla Herguedas, Pedro Montesinos, Ebe Giovannini, Julia Angiolini, Pedro Alcalde, Riccardo Chinni, Sandra del Rio Bonnin, Marta Monzón, Eduard Puig Solé, Luis Gerald Montero, David Pérez Vallejo, Fernando J. Elizondo-Garza, Miguel Molina-Alarcón, Alicia González Escamilla, José Nocito, Josep Manuel Berenguer Alarcón, Josep Cerdà, Gabriel de Toledo Piza, Jerónimo Vida, José Luís de Carles, Estefanía Aimar, Uli Marchsteiner, Luis Paulino Salas, Ricardo Atienza, Ivana Rossell, Leonel de la Pava, Enric Mir, Cesc Cels i López, Rosa Mª Cibrián Ortiz de Anda., La simultánea envuelta para regalo, es una obra artística basada en 40 paisajes sonoros reales provenientes de todo el mundo, que se han grabado simultáneamente a mediodía del día de mi santo, el 2 de abril del 2020, en plena pandemia. La grabación final, de 3 minutos de extensión en total, contiene 40 cortes sonoros, de 4,5 segundos cada uno, empalmados de forma consecutiva, respetando el orden en que se recepcionaron las grabaciones originales. Los autores han cedido sus derechos para poder hacer este compendio, en el que ha participado muy activamente el técnico de sonido Héctor Balart Armengol, compatibilizando los diferentes lenguajes de cada deriva sonora, y realizando la elección aleatoria de sus valores estéticos más representativos. Esta obra se presentó como primicia el 14 de octubre del 2020 en la Bienal del Pensamiento del Ayuntamiento de Barcelona, para la mesa redonda Sonidos, Ruidos, Silencios. Hacia una ecología acústica urbana en la era digital. Participantes: Francesc Daumal i Domènech, Fernando Valdés, Rosa María Alsina, Antonio de Clemente, Vicent Matamoros, Laura Puig, Oriol Server Yerga, Carlos Gómez Caballero, Valentin Martín Fanjul, Belen Casla Herguedas, Pedro Montesinos, Ebe Giovannini, Julia Angiolini, Pedro Alcalde, Riccardo Chinni, Sandra del Rio Bonnin, Marta Monzón, Eduard Puig Solé, Luis Gerald Montero, David Pérez Vallejo, Fernando J. Elizondo-Garza, Miguel Molina-Alarcón, Alicia González Escamilla, José Nocito, Josep Manuel Berenguer Alarcón, Josep Cerdà, Gabriel de Toledo Piza, Jerónimo Vida, José Luís de Carles, Estefanía Aimar, Uli Marchsteiner, Luis Paulino Salas, Ricardo Atienza, Ivana Rossell, Leonel de la Pava, Enric Mir, Cesc Cels i López, Rosa Mª Cibrián Ortiz de Anda.

Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCL <30 mL/min), received a single 80-mg oral dose of osimertinib and standard PK measures were assessed. Part B: patients with SRI were treated for 3 months to obtain safety data, if deemed clinically appropriate. The geometric mean osimertinib plasma concentrations were higher in patients with SRI (n = 7) vs NRF (n = 8) and were highly variable. Osimertinib exposure based on Cmax and area under the plasma concentration-time curve, was 1.19-fold (90% CI: 0.6, 2.0) and 1.85-fold (90% CI: 0.9, 3.6), respectively, higher for patients with SRI vs patients with NRF, with no clear correlation between CrCL and exposure. No new safety signals were identified after 12 weeks of osimertinib 80 mg continuous dosing. PK parameters pooled across this study and other phase I, II, and III osimertinib clinical studies (exploratory population PK analysis), showed minimal correlation between CrCL and total clearance. In conclusion, no dose adjustment is required for osimertinib for patients with SRI., Si

In recent randomized, placebo-controlled, phase III trials, highly purified cannabidiol demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut syndrome or Dravet syndrome. It is anticipated that antiepileptic drugs such as stiripentol and valproate will be administered concomitantly with cannabidiol. This trial evaluated the effect of cannabidiol on steady-state pharmacokinetics of stiripentol or valproate in patients with epilepsy, and the safety and tolerability of cannabidiol. This phase II, two-arm, parallel-group, double-blind, randomized, placebo-controlled trial recruited male and female patients with epilepsy aged 16-55 years. Patients receiving a stable dose of stiripentol or valproate were randomized 4:1 to receive concomitant double-blind cannabidiol or placebo. Patients received plant-derived, highly purified cannabidiol medicine (Epidiolex® in the USA; Epidyolex® in the EU; 100 mg/mL oral solution) at a dose of 20 mg/kg/day from day 12 to 26, following a 10-day dose-escalation period. Blood samples for pharmacokinetic evaluations were collected on days 1 and 26 before stiripentol/valproate dosing and up to 12 h postdose. Treatment-emergent adverse events (AEs) were recorded. In total, 35 patients were recruited to the stiripentol arm (n = 14) or the valproate arm (n = 21). Both the safety and the pharmacokinetic populations of the stiripentol arm comprised 14 patients (2 placebo; 12 cannabidiol). The safety population of the valproate arm comprised 20 patients (4 placebo; 16 cannabidiol; one withdrew before receiving treatment); the pharmacokinetic population comprised 15 patients (3 placebo; 12 cannabidiol). Concomitant cannabidiol led to a small increase in stiripentol exposure (17% increase in maximum observed plasma concentration [Cmax]; 30% increase in area under the concentration-time curve over the dosing interval [AUCtau]). Concomitant cannabidiol also had little effect on valproate exposure (13% decrease in Cmax; 17% decrease in AUCtau) or its metabolite, 2-propyl-4-pentenoic acid (4-ene-VPA) (23% decrease in Cmax; 30% decrease in AUCtau). All changes in exposure are expressed as the dose-normalized geometric mean (CV%) day 26 to day 1 ratio. The most common AE was diarrhea; most AEs were mild. Two patients discontinued cannabidiol because of serious AEs (rash [n = 1] in the stiripentol arm; hypertransaminasemia [n = 1] in the valproate arm). A separate in vitro study investigated the bidirectional effect of cannabidiol, or its metabolite 7-carboxy-cannabidiol, on valproate plasma protein binding; no change in plasma protein binding was observed for either compound. The clinical relevance of the increase in stiripentol exposure is unknown; patients receiving cannabidiol and stiripentol concomitantly should be monitored for adverse reactions as individual patient responses may vary. Coadministration of cannabidiol did not affect the pharmacokinetics of valproate or its metabolite, 4-ene-VPA, in adult patients with epilepsy. Safety results were consistent with the known safety profile of cannabidiol at a dose of 20 mg/kg/day. Clinicaltrials.gov: NCT02607891., Si

Background: Low-cardiac output syndrome (LCOS) after cardiac surgery secondary to systemic hypoperfusion is associated with a higher incidence of renal and neurological damage. A range of effective therapies are available for LCOS. The beneficial systemic effects of levosimendan persist even after cardiac output is restored, which suggests an independent cardioprotective effect. Methods: A double-blind clinical trial was conducted in patients with a confirmed diagnosis of LCOS randomized into two treatment groups (levosimendan vs. dobutamine). Monitoring of hemodynamic (cardiac index, systolic volume index, heart rate, mean arterial pressure, central venous pressure, central venous saturation); biochemical (e.g. creatinine, S100B protein, NT-proBNP, troponin I); and renal parameters was performed using acute kidney injury scale (AKI scale) and renal and brain ultrasound measurements [vascular resistance index (VRI)] at diagnosis and during the first 48 h. Results: Significant differences were observed between groups in terms of cardiac index, systolic volume index, NT-proBNP, and kidney injury stage at diagnosis. In the levosimendan group, there were significant variations in AKI stage after 24 and 48 h. No significant differences were observed in the other parameters studied. Conclusion: Levosimendan showed a beneficial effect on renal function in LCOS patients after cardiac surgery that was independent from cardiac output and vascular tone. This effect is probably achieved by pharmacological postconditioning., LG is supported by the Miguel Servet program from the ISCIII (Spain) (“Miguel Servet II” program, CPII18/00030) and Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (C-0028-2018). CS is supported by a grant from the ISCIII (Spain) (“PFIS” program, FI16/00241). CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an ISCIII project (Spain)., Sí